Key Takeaways
- Muted Q4, underlying growth ~5–6%: Reported top-line was held back by a residual CMO fire supply impact (~3–3.5% of sales) and soft distributed-portfolio demand, masking healthy secondary offtake.
- Supply constraints fully resolved from Q1: Management gave an explicit reassurance that beginning April and Q1 FY27, no supply constraints remain, with alternative contingencies now in place.
- Double-digit ambition undiluted, innovation-led: The company reiterated its double-digit growth intent, anchored on accelerating innovative launches, reducing launch lags, and a freshness index target of ~10% of top-line.
- Margins to be maintained, not expanded: After 290 bps of EBITDA improvement in FY26, the objective is to hold margins and reinvest for upcoming launches rather than target further expansion.
- What to watch next quarter: Whether the GenMed business returns to the guided 6–8% growth now that supply is normalised, the pace of the two expected oncology launches and one adult vaccine launch in the next six months, and any margin impact from the reinvestment cycle.
Supply Constraints & Recovery
- CMO fire caused a multi-quarter drag: A fire at a significant CMO in April of the prior year triggered a long cycle of remediation, site re-validation and quality assurance. Calpol was impacted for the first six months and returned by end of Q3, but tail-end brands still lost INR28–30 crores in Q4 alone.
- Q4 top-line hit quantified: The residual supply impact was ~3–3.5% of top-line for the quarter, plus some phasing from delayed vaccine consignments that arrived in March but spilled into Q1 on clearances.
- GenMed flat for the full year, adjusted growth 3–4%: The general medicines portfolio lost more than INR100 crores worth of supply across FY26; stripping that out, underlying GenMed growth was 3–4%.
- Resolution is categorical: Management stated that from April and Q1 of the new financial year, there are no supply constraints, with robust business continuity planning and alternative contingencies now in place. Delayed vaccine shipments will also reflect in Q1.
Akshikar: "I can only reassure you, given the visibility and the oversight that I along with the management team have, beginning the month of April and Q1 of our new financial year, we don't have any supply constraints."
Portfolio Performance
- Promoted brands outpaced the market: Augmentin and Calpol grew ahead of market by 3–4 percentage points, while secondary sales analysis showed healthy high-single-digit or double-digit off-take, confirming underlying demand is intact.
- Vaccines delivered double-digit growth: The pediatric vaccines business and adult vaccines (Shingrix) both performed, with the portfolio growing 11–12% blended for FY26. Shingrix has been pivoted to a cardiovascular-metabolic strategy exploiting the bidirectional link between CV/metabolic disease and herpes prevention.
- Trelegy Ellipta held share despite a wave of generics: Over ~10 months, 8–10 generic versions of the triple combination launched, yet Trelegy grew patient share and market share in the last month of Q4 and first month of Q1. Management attributes this to device quality and ease of use that generics have not replicated.
- Specialty respiratory built a base: Nucala is clocking 100–120 patients per month in severe asthma, while Trelegy Ellipta sustained market share.
- Oncology grew, with a catalyst ahead: Zejula (ovarian cancer) and Jemperli (endometrial cancer) continued to grow; the Ruby-1 trial approval unlocked value in first-line treatment of endometrial cancer.
- Soft spots were Eltroxin and the distributed portfolio: These tail-end brands showed soft demand and did not deliver the expected tailwind, diluting overall growth.
Akshikar: "in spite of having 8 to 10 generic versions of the combination, of the triple combination, I don't think we have the -- still anyone which has a device or the quality of ease of usage as Trelegy Ellipta."
Innovation Pipeline & Launches
- Launch lag compressed to 6–8 months: Belantamab (Blenrep), an antibody-drug conjugate for relapsed refractory multiple myeloma, received market authorization with a launch lag of just 6–8 months from the first US launch, and is launching very soon.
- Two significant oncology launches and one adult vaccine launch in the next six months: Management committed to at least one significant launch in the next four quarters for an unmet need, and specified two in oncology plus one in adult vaccines within six months.
- Bepirovirsen could be a functional cure in hepatitis B: The compound showed ~25% of patients achieving complete functional cure from a baseline of almost nothing existing. A partnership was signed in China, and market authorization in India is estimated in the next six months, within this financial year.
- RSV vaccine and liver disease compounds progressing: A Subject Expert Committee approval for the RSV vaccine is in hand, awaiting market authorization. In liver disease, more news is expected in the next 12–18 months on Bepirovirsen (chronic hepatitis B) and Efruxifermin (MASH).
- Clinical trial footprint expanding: India now has 24 ongoing global trials, up from 16 two quarters ago, and is included in Phase 3/3B trials for B7-H4, an antibody-drug conjugate. Velzatinib trials for gastric cancer are also ongoing.
- Freshness index target of ~10% of top-line: Management stated the intent for the innovative portfolio to contribute around 10% of revenue, though the annual revenue contribution from specialty and innovation was not disclosed beyond the 6% Q4 figure.
Akshikar: "for the first time you have, I think, 25% of the patients getting complete functional cure. And that's from a baseline of almost nothing existing, you have something which is for the first time actually talking of a potential functional cure."
Margins & Reinvestment
- FY26 profitability improved sharply: Gross margins expanded 190 bps, SG&A efficiencies came from field force productivity and AI-led optimization, and EBITDA ratios improved 290 bps to 34%.
- Three margin levers identified: The expansion was driven by shifting mix away from price-controlled products, competitive pricing that maintained peer-group price-led growth, and reducing cost of goods for NLEM products through active sourcing changes and forward contracts.
- NLEM volume growth offset price controls: Each asset included in NLEM has grown volumes at least two times over four years, helping absorb the margin pressure from price controls.
- Margins will now be maintained, not expanded: The objective is to hold margins and reinvest in the business for upcoming launches. Management was explicit that it would rather invest money in growing the business than target further margin expansion as a primary endpoint.
- Specialty margin profile not disclosed: When asked about the margin profile of the specialty portfolio versus the base business (imports vs local manufacturing) and how to navigate NLEM exposure with RM inflation, management did not provide a specific comparison or quantification, answering instead with a general statement on top-line focus and cost optimization.
Akshikar: "Our objective will be to maintain the margins and not to -- we would love to reinvest in the business... we would rather invest that money in growing the business with the expectation that we are able to hold the margins."
Strategic Bets: Adult Vaccines & Oncology Access
- Shingrix positioned for a path-breaking year: Management expects the next 12 months to be transformational for the shingles prevention vaccine, with strong high-double-digit numbers for the vaccines business overall. The strategy now links Shingrix to cardiovascular and metabolic disease prevention.
- Oncology public-account unlock in sight: Progress on accessing public accounts (CGHS, Army, Railways, ESIC) is expected in the next six to eight months, which would open a large new channel for the oncology portfolio.
- Patient assistance programs are not launch-heavy: When an analyst suggested assistance programs are higher at launch and taper as a product matures, management pushed back, stating the programs do not differentiate across the product lifecycle. Pricing strategy and market sizing for Bepirovirsen were declined as premature.
Akshikar: "the next 12 months, this coming financial year, especially for shingles prevention vaccine or Shingrix, will be path-breaking."
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Supply constraints resolved | No supply constraints; alternative contingencies in place | From April / Q1 FY27 |
| GenMed growth recovery | Return to 6–8% top-line growth | FY27 (post-supply normalisation) |
| Double-digit growth ambition | Stated intent undiluted, innovation-led | Ongoing (no terminal date) |
| At least one significant launch | For an unmet need with significant value per asset | Next four quarters |
| Two oncology launches, one adult vaccine launch | Specific count of near-term launches | Next six months |
| Bepirovirsen market authorization | Estimated approval in India | Next six months / this financial year |
| Oncology public-account access | Progress on CGHS, Army, Railways, ESIC accounts | Next six to eight months |
| Freshness index target | Innovative portfolio at ~10% of top-line | No date (directionally stated) |
| Margins maintained, not expanded | Hold margins and reinvest for launches | Ongoing |
| Liver disease news flow | Bepirovirsen and Efruxifermin updates | Next 12–18 months |
Key Metrics
| Metric | Q4 FY26 |
|---|---|
| Revenue | ₹64,000–₹65,000 cr (industry per IQVIA), GSK standalone sales up 2% YoY |
| EBITDA margin | 35%, improved 1 ppt YoY on better gross margins and cost management |
| EBITDA growth | 5% YoY |
| PAT growth | 6% YoY |
| Full-year revenue growth | 2% YoY |
| Full-year EBITDA margin | 34%, improved 290 bps YoY |
| Full-year PAT (excl. exceptionals) | >₹1,000 cr, first time crossing this milestone |
| Full-year EPS | ₹59.6 per share, up 10% YoY |
| Gross margin (full year) | Up 190 bps YoY |
| Return on capital employed (full year) | 61.0% |
| Cash position (year-end) | ₹2,745 cr |
| Final dividend | ₹57 per share |
| Innovative portfolio contribution | 6% of Q4 sales, up from ~2% on a like-to-like basis in prior-year Q4 |
| Pediatric vaccines growth (full year) | 9% |
| Vaccines portfolio blended growth (full year) | >11–12% |
| General Medicines growth (full year) | ~flat, underlying growth 3–4% adjusted for >₹100 cr supply-constraint impact |
| Supply-constraint impact on Q4 top-line | Shaved off ~3–3.5% of growth |
| NLEM exposure | ~40% of business |
| Oncology field force | ~25 people for solid tumors, hematology team recruitment started |
| Ongoing clinical trials in India | 26 trials, up from 16 two quarters ago |
| Multiple myeloma annual incidence (India) | ~18,000 new cases, prevalence ~40,000–45,000 patients |